Why Taiwan medical advertising rules are stricter than they look
Taiwan regulates medical and pharmaceutical advertising primarily under the Pharmaceutical Affairs Act, enforced by the TFDA — medicament advertisements require prior approval (Article 66), prohibit publicity via testimonial or news-report framing (Article 68), and ban any non-medicament product from claiming medical efficacy at all (Article 69, the Act's highest penalty band). Separately, the Fair Trade Act (Article 21) prohibits false or misleading representations able to affect a trading decision — superlative claims ("No. 1", "the best") and unsubstantiated effect claims are the Fair Trade Commission's own named examples. The Consumer Protection Act (Article 22) then makes advertised content legally binding: a business must perform in accordance with what its ads promised.
This self-check walks your actual ad copy through the risk areas that most often trip up clinic and medical advertising in Taiwan, flags the specific phrase that triggered each one, explains which law it touches, and suggests a compliant rewrite. It's the same discipline our Taiwan team applies from our real Taipei office — see our Taiwan aesthetic clinic marketing page for the full strategy layer.
What this checker looks for
6 rule categories, drawn from the sources cited below — each one covers a specific pattern our checker scans your pasted text for:
- Off-label or unapproved-use promotion — The TFDA has stated off-label promotion is not allowed (FDA Letter No. 1101460212, 24 Dec 2021) — advertising a pharmaceutical or medical treatment for a use beyond its officially approved indication. A Taichung District Court case upheld an NT$200,000 fine on exactly this basis, treating it as improper advertising prohibited under Pharmaceutical Affairs Act Article 68's general clause against advertising 'by any other improper means.' Source
- Non-medicament product claiming medical efficacy — Pharmaceutical Affairs Act Article 69 prohibits any pictorial or literal description regarding the medical efficacy of a product other than a registered medicament — a cosmetic, supplement, or device claiming to cure or treat a disease is advertising medical efficacy it has no registered basis to claim. Article 69 violations carry the highest penalty band in the Act (NT$600,000–25,000,000) plus confiscation and destruction of the advertised product. Source
- Testimonials, interviews or news-report framing implying medical claims — Pharmaceutical Affairs Act Article 68 prohibits publicising a medicament by releasing an interview or news report, or by making use of another person's name to warrant efficacy — framing that dresses advertising as editorial content or a personal testimonial is exactly the pattern this article targets. Article 70 separately treats an interview or news report implying medical efficacy as a medicament advertisement in its own right, meaning it needs the same prior approval as a direct ad. Source
- Superlative or unsubstantiated claims — Fair Trade Act Article 21 prohibits false or misleading representations on matters able to affect a trading decision. The Fair Trade Commission's own guidelines give superlative terms ('No. 1', 'champion', 'the biggest') used without probative data as a typical example of a violation. Source
- Absolute or guaranteed-outcome claims — The Fair Trade Commission's Article 21 guidelines separately flag claims asserting a specific (usually medical) effect without scientific or experimental support as a typical false-or-misleading violation. A guaranteed or absolute-outcome claim for any treatment or service is exactly this pattern, and for pharmaceutical/medical products additionally risks an Article 69 medical-efficacy violation if the product isn't a registered medicament for that claim. Source
- Advertised claims become a binding service warranty — Consumer Protection Act Article 22 requires traders to ensure the accuracy of advertisement content and not provide less than what is stated in it — after a contract is made, the business must perform in accordance with what the advertisement promised. A specific promise or outcome commitment in ad copy becomes something the business is legally obligated to deliver, not just persuasive language. Source
Methodology — where this checklist comes from
Every rule's primary source is law.moj.gov.tw, Taiwan's own official Laws & Regulations Database, fetched and read in full this session (Pharmaceutical Affairs Act Articles 66/68/69/70, Fair Trade Act Article 21, Consumer Protection Act Article 22) — a deliberately higher sourcing bar than a vendor doc or law-firm marketing page. The one exception is the specific TFDA administrative position on off-label promotion (Letter No. 1101460212), which wasn't found at a stable public TFDA URL this session and is corroborated via a named legal-practice guide (ICLG) that quotes the letter directly, cross-referenced against the Act's own Article 68 text. It is not a substitute for legal advice: treat a “no flags” result as a reasonable first pass, not clearance.
Rules current as of: July 2026